Treatment of visceral leishmaniasis in children with liposomal amphotericin B

L. Di Martino; R. N. Davidson; R. Giacchino; S. Scotti; F. Raimondi; E. Castagnola; L. Tasso; A. Cascio; L. Gradoni; M. Gramiccia; M. Pettoello- Mantovani; A. D M Bryceson

doi:10.1016/S0022-3476(97)70165-3

Treatment of visceral leishmaniasis in children with liposomal amphotericin B

L. Di Martino, R. N. Davidson, R. Giacchino, S. Scotti, F. Raimondi, E. Castagnola, L. Tasso, A. Cascio, L. Gradoni, M. Gramiccia, M. Pettoello- Mantovani, A. D M Bryceson

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cure the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).

Original language	English
Pages (from-to)	271-277
Number of pages	7
Journal	Journal of Pediatrics
Volume	131
Issue number	2
DOIs	https://doi.org/10.1016/S0022-3476(97)70165-3
Publication status	Published - 1997

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/S0022-3476(97)70165-3

Fingerprint Dive into the research topics of 'Treatment of visceral leishmaniasis in children with liposomal amphotericin B'. Together they form a unique fingerprint.

Cite this

Treatment of visceral leishmaniasis in children with liposomal amphotericin B. / Di Martino, L.; Davidson, R. N.; Giacchino, R.; Scotti, S.; Raimondi, F.; Castagnola, E.; Tasso, L.; Cascio, A.; Gradoni, L.; Gramiccia, M.; Pettoello- Mantovani, M.; Bryceson, A. D M.

In: Journal of Pediatrics, Vol. 131, No. 2, 1997, p. 271-277.

Research output: Contribution to journal › Article › peer-review

@article{1d7318c4879048fea56b34fb5fc509f9,

title = "Treatment of visceral leishmaniasis in children with liposomal amphotericin B",

abstract = "We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cure the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).",

author = "{Di Martino}, L. and Davidson, {R. N.} and R. Giacchino and S. Scotti and F. Raimondi and E. Castagnola and L. Tasso and A. Cascio and L. Gradoni and M. Gramiccia and {Pettoello- Mantovani}, M. and Bryceson, {A. D M}",

year = "1997",

doi = "10.1016/S0022-3476(97)70165-3",

language = "English",

volume = "131",

pages = "271--277",

journal = "Journal of Pediatrics",

issn = "0022-3476",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Treatment of visceral leishmaniasis in children with liposomal amphotericin B

AU - Di Martino, L.

AU - Davidson, R. N.

AU - Giacchino, R.

AU - Scotti, S.

AU - Raimondi, F.

AU - Castagnola, E.

AU - Tasso, L.

AU - Cascio, A.

AU - Gradoni, L.

AU - Gramiccia, M.

AU - Pettoello- Mantovani, M.

AU - Bryceson, A. D M

PY - 1997

Y1 - 1997

N2 - We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cure the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).

AB - We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cure the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).

UR - http://www.scopus.com/inward/record.url?scp=0030706193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030706193&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(97)70165-3

DO - 10.1016/S0022-3476(97)70165-3

M3 - Article

C2 - 9290615

AN - SCOPUS:0030706193

VL - 131

SP - 271

EP - 277

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -